Cvsi synthetic cbd
0.97 USD The Company’s specialty pharma business segment is focused on developing and commercializing therapeutics utilizing synthetic Cannabidiol (CBD) across CV Sciences, Inc. Reports Third Quarter 2018 Financial Results - 07.11.2018 · CV Sciences, Inc. operates two distinct business segments: a drug development division focused on developing and commercializing novel therapeutics utilizing synthetic CBD; and, a consumer product